Does Insurance Cover Semaglutide? GLP-1 Savings Programs & Patient Assistance Explained

You've been prescribed a GLP-1 medication — or you're about to be — and the first question isn't whether it works. It's how you're going to pay for it. At $900–$1,400 per month retail, cost is the single biggest barrier to starting and staying on treatment.

The good news: most patients don't actually pay the full list price. Between insurance coverage, manufacturer savings cards, and patient assistance programs, there are real options to bring your out-of-pocket cost down significantly. The bad news: finding the right program for your situation requires knowing where to look.

This guide covers every major pathway to making GLP-1 medications more affordable — and a few red flags to watch out for along the way.

Insurance Coverage: The Current Landscape

Whether insurance covers your GLP-1 medication depends on three factors: your plan type, which medication you're prescribed, and why it's prescribed (diabetes vs. weight management).

Here's the general picture across major insurance categories:

Medicare Part D

Medicare Part D generally covers GLP-1 medications prescribed for type 2 diabetes (like Ozempic or Mounjaro). However, anti-obesity medications prescribed specifically for weight management — including Wegovy and Zepbound — have historically been excluded from Part D coverage. Legislative efforts to expand coverage are ongoing, but as of 2026, most Medicare beneficiaries seeking weight-loss-specific treatment face the full retail cost.

Medicaid

Medicaid coverage varies significantly by state. Some states cover FDA-approved anti-obesity medications; many do not. Even in states with coverage, prior authorization is common, and formulary placement can limit which specific brand is covered. Check your state's Medicaid drug formulary or call member services for details.

Commercial (Employer-Sponsored) Plans

This is where coverage is most likely. However, a meaningful percentage of large employer plans still exclude anti-obesity medications from their formularies. The trend is improving — more employers are adding obesity drug coverage each year — but "commercial insurance" does not automatically mean "covered." For diabetes indications, coverage is significantly more common.

If your plan covers GLP-1s, expect a copay of $50–$200/month after meeting your deductible. Prior authorization is almost always required.

Manufacturer Savings Programs

Both major GLP-1 manufacturers offer savings programs for eligible patients. These can dramatically reduce out-of-pocket costs — but they come with important eligibility restrictions.

Novo Nordisk Programs (Wegovy & Ozempic)

Novo Nordisk offers two main assistance pathways:

• Savings card for commercially insured patients: Eligible patients with commercial (non-government) insurance may pay as low as $0/month for Wegovy or Ozempic, up to an annual maximum benefit. Eligibility, copay amounts, and annual caps change periodically — check the manufacturer's patient portal directly.
• Patient Assistance Program (PAP): For uninsured or underinsured patients meeting income-based eligibility criteria, Novo Nordisk offers medication at no cost through their PAP. This is a separate application process with income documentation requirements.

Eli Lilly Programs (Mounjaro & Zepbound)

Eli Lilly has taken an aggressive approach to patient access:

• Savings card for commercially insured patients: Similar to Novo Nordisk, eligible commercially insured patients may pay significantly reduced copays. Specifics vary — check Lilly's patient resources directly.
• Zepbound vials (lower-cost format): Lilly offers Zepbound in a multi-dose vial format at a substantially lower list price than the single-use auto-injector pens. This is particularly relevant for patients paying out of pocket or with high-deductible plans.
• LillyDirect: Lilly's direct-to-patient platform offers transparent pricing and home delivery for certain medications. This can simplify the cost picture for patients navigating complex pharmacy benefits.

Compounding Pharmacies & Generic Alternatives

Compounding pharmacies have been a significant source of lower-cost semaglutide during FDA-declared supply shortages. However, the landscape has shifted:

• FDA shortage status matters. Compounding pharmacies are permitted to produce copies of FDA-approved drugs during official shortages. When the FDA removes a drug from its shortage list, the legal basis for compounding narrows significantly.
• As of 2026, semaglutide has been removed from the FDA shortage list, which limits the availability of compounded semaglutide. Tirzepatide supply status may differ — check the FDA's current shortage database.
• Compounded medications are not FDA-approved and do not undergo the same manufacturing standards as branded products. Quality and consistency can vary between compounding pharmacies.
• No generic semaglutide exists yet. The earliest patent expirations that could enable generics are several years away.

How to Check Your Insurance Coverage: Step by Step

Before assuming you'll pay full price, run through this process:

1. Find your formulary. Your insurance plan's drug formulary lists which medications are covered and at what tier. Most insurers publish this on their member portal. Search for "Wegovy," "Ozempic," "Mounjaro," or "Zepbound" specifically.
2. Call member services. The number on the back of your insurance card. Ask: "Does my plan cover [medication name] for chronic weight management?" and "What are the prior authorization requirements?" Document the representative's name and reference number.
3. Ask about prior authorization. Almost all GLP-1 prescriptions require prior authorization — your physician submits clinical documentation proving medical necessity. Ask what criteria must be met (BMI threshold, documented weight-related conditions, etc.).
4. Check your benefit design. Even if the drug is covered, understand your cost-sharing: What tier is it on? What's your copay or coinsurance? Have you met your deductible? Is there a separate specialty pharmacy requirement?
5. Ask about step therapy. Some plans require you to try (and fail with) a lower-cost medication before approving a GLP-1. This is called "step therapy" or "fail-first" and is a common cost-control measure.
6. Apply the savings card. Once you know your insurance covers the medication, apply the manufacturer's savings card at the pharmacy to reduce your remaining copay. Your physician or pharmacist can help with enrollment.

If your plan doesn't cover the medication, ask your physician about an appeal. Many insurers will reconsider coverage when presented with sufficient clinical documentation — especially if you have weight-related comorbidities like type 2 diabetes, hypertension, or obstructive sleep apnea.

Red Flags: What to Avoid When Seeking Affordable GLP-1s

The demand for affordable GLP-1 medications has created a market for bad actors. Watch for these warning signs:

• "Guaranteed approval" without a medical evaluation. Any legitimate prescriber must evaluate your health profile before prescribing. If a website promises a prescription without a physician assessment, it's either illegal or unsafe — or both.
• Upfront payments for "membership" to access savings programs. Manufacturer savings cards are free to apply for. You should never pay a third party to "enroll" you in a savings program that the manufacturer offers directly.
• Prices that seem impossibly low. If someone offers brand-name Wegovy for $99/month with no insurance, the product is likely compounded (not FDA-approved), counterfeit, or sourced from outside the regulated U.S. supply chain.
• No prescriber verification. Legitimate telehealth platforms will tell you who your prescribing physician is — by name, with a verifiable medical license. If you can't identify your doctor, that's a problem.
• Pressure to "act now" before prices increase. High-pressure sales tactics are a red flag in any medical context. Legitimate programs don't use artificial urgency.

At PropPilot, every patient receives a consultation with a board-certified, licensed physician who prescribes only FDA-approved medications. You can verify your physician's credentials and review our Telehealth Consent before starting.

Telehealth: A Practical Alternative

If your insurance doesn't cover GLP-1s for weight management — or the prior authorization process is too lengthy — physician-supervised telehealth offers a streamlined alternative.

Telehealth doesn't bypass the need for a prescription. What it does is remove the overhead of specialist referrals, multi-week appointment waitlists, and office-visit billing. For patients paying out of pocket, this translates to a more predictable and often lower total cost.

PropPilot includes physician consultation, ongoing medical supervision, and prescription management in a transparent monthly fee. For patients whose insurance doesn't cover anti-obesity medications, this is often the most practical path to medically supervised treatment. You can read more about how the telehealth prescription process works.

The Bottom Line

Insurance coverage for GLP-1 medications is improving, but it's far from universal. The key is knowing your options:

• Check your formulary first. Many commercially insured patients have coverage and don't realize it.
• Apply for manufacturer savings cards. These can reduce copays to near-zero for eligible patients.
• Explore patient assistance programs if you're uninsured and meet income criteria.
• Be skeptical of unusually cheap options that bypass standard medical evaluation or use non-FDA-approved products.
• Consider telehealth if your insurance doesn't cover the medication and you're paying out of pocket.

Cost should not be the reason you forgo medically appropriate treatment. Between insurance benefits, savings programs, and physician-supervised telehealth, most patients have more options than they initially realize.